| 5.5 0.46 (9.13%) | 07-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.42 |
1-year : | 7.5 |
| Resists | First : | 5.5 |
Second : | 6.42 |
| Pivot price | 4.97 |
|||
| Supports | First : | 4.51 |
Second : | 3.9 |
| MAs | MA(5) : | 4.96 |
MA(20) : | 4.77 |
| MA(100) : | 3.93 |
MA(250) : | 5.7  |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 75.8 |
D(3) : | 63.5 |
| RSI | RSI(14): 61.2 |
|||
| 52-week | High : | 10.58 | Low : | 1.89 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CNSP ] has closed below upper band by 9.7%. Bollinger Bands are 39.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.51 - 5.53 | 5.53 - 5.55 |
| Low: | 4.96 - 4.98 | 4.98 - 5 |
| Close: | 5.46 - 5.5 | 5.5 - 5.54 |
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
Thu, 02 Jul 2026
CNS Pharmaceuticals posts investor presentation; details $22.5M financing and strategic pivot - TradingView
Thu, 02 Jul 2026
Strategic pivot at CNS Pharmaceuticals (NASDAQ: CNSP) backed by $22.5M PIPE - Stock Titan
Tue, 05 May 2026
CNS Pharma sees 250% spike from oversubscribed private placement - Mugglehead Investment Magazine
Mon, 04 May 2026
CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing - ACCESS Newswire
Mon, 04 May 2026
CNS Pharmaceuticals raises $22.5 million in private placement - Investing.com
Mon, 04 May 2026
CNS Pharmaceuticals (NASDAQ: CNSP) Secures $22.5M Private Placement Financing - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 12.5 (%) |
| Shares Short | 36 (K) |
| Shares Short P.Month | 49 (K) |
| EPS | -24.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.09 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -113 % |
| Return on Equity (ttm) | -298.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -11.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.23 |
| PEG Ratio | 0 |
| Price to Book value | 61.11 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|